Effectiveness of a Multicomponent Digital Therapeutic Program on Inhaled Medication Adherence in Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial.
Hanna Wu, Fen Dong, Yanan Cui et al.
✦ AI-curated · Sources linked
In 30 seconds
This 24-week, prospective, open-label randomized controlled pilot trial evaluated a multicomponent digital program in patients with COPD prescribed pressurized metered-dose inhalers. Participants received electronic inhaler monitoring; the intervention group also received reminders, adherence feedback, educational content, and clinician-supported follow-up, while controls received usual care. Among 158 randomized participants, electronically monitored adherence was higher with the program than with usual care (59.5% vs 33.1%, P =.009). Self-reported adherence and most clinical outcomes did not differ significantly, although an exploratory analysis found more intervention participants achieved a clinically meaningful COPD Assessment Test improvement.
Key findings
- Electronically monitored adherence was 59.5% with the digital program versus 33.1% with usual care (P =.009).
- Adherence declined in both groups, from 85.3% to 43.0% in the intervention group and from 76.8% to 11.9% in controls.
- No significant between-group differences were observed in exacerbations, quality of life, symptom burden, lung function, or mental health.
- In an exploratory analysis, intervention participants were more likely to achieve the COPD Assessment Test minimal clinically important difference (odds ratio 2.21, 95% CI 1.11-4.41; P =.02).
Why it matters
Objective monitoring paired with reminders and behavioral support may address a practical barrier to COPD management: difficulty tracking and sustaining inhaler use. The adherence improvement is clinically relevant as a care-process outcome, but the absence of significant differences in most clinical outcomes means that improved monitoring adherence should not be assumed to translate into broader health benefits.
What to keep in mind
This was a pilot trial with 24 weeks of follow-up. Self-reported adherence did not differ, and most clinical outcomes were not significantly different; the COPD Assessment Test finding came from an exploratory analysis.